Agilent Technologies (A) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Key financial and operational highlights

• Achieved 6% core top-line growth in Q3, with strong performance in Pharma, CAM, and CDMO segments; Pharma QA/QC grew double digits, especially in Europe with mid-teens growth.

• Instrument sales showed steady progression throughout the quarter, marking a shift from previous end-loaded quarters.

• Margins were impacted by tariffs, investments in commercial expansion, and increased variable pay; Q3 marked the low point for margins, with sequential improvement of 230 basis points expected in Q4.

• Pricing initiatives contributed 100 basis points to margin improvement in Q3, with further gains expected as surcharges are implemented in Q4 and into 2026.

• Service business remains strong, with satisfaction scores above 90% and significant growth potential, especially in China.

Market and product trends

• Early stages of replacement cycles for Infinity II LC and 8850 GC instruments, with productivity gains driving repeat purchases; cycles expected to continue into 2026.

• CAM segment delivered 10% growth in both chemicals and advanced materials, supported by greenfield investments, supply chain consolidation, and semiconductor demand.

• China remains a stable and strategic market, with high innovation in pharma and biopharma, strong battery and semiconductor research, and a large upcoming stimulus opportunity.

• Local competition in China is present in lower-end instruments but limited in high-end analytical tools due to technical and service barriers.

• PFAS business grew 50% globally, with temporary softness in the US due to regulatory uncertainty; long-term growth expected as regulations and litigation drive demand.

Strategic initiatives and outlook

• CDMO (NASD) segment posted 20% growth in Q3, with bookings extending into 2027 and a shift toward more commercial batches; $700 million capacity investment coming online in Q4 2026.

• BioVectra acquisition is yielding synergies, especially in GLP-1s and ADCs, with process improvements supporting future capacity.

• Prudent approach to guidance, but long-term growth plan targets 5-7% with positive outlook for mid-single-digit growth and margin expansion in the coming year.

• M&A strategy remains disciplined, focused on high-quality targets in faster-growing, recurring revenue areas; strong balance sheet supports future deals.

• Ignite program continues to drive cost efficiencies and value creation, with ongoing investments in innovation and customer connectivity.